Podcasts about Memorial Sloan Kettering Cancer Center

This week on Health Matters, Courtney talks with urologic oncologist Dr. Michael Feuerstein of Columbia and NewYork-Presbyterian The One, a new center for advanced care in Westchester, to discuss the importance of screening for prostate cancer. Dr. Feuerstein explains how blood tests work to detect prostate cancer, explores the latest advancements in treatment, and debunks common myths and misunderstandings about prostate health. ___Dr. Michael Feuerstein, MD, MPH, is the chief of urology at NewYork-Presbyterian Westchester and assistant professor in the Department of Urology at Columbia University Vagelos College of Physicians and Surgeons. Dr. Feuerstein is a board-certified urologist with over ten years of experience, specializing in minimally-invasive surgery for prostate, kidney, and bladder cancer. He received his medical degree and completed his urology residency training at Albany Medical Center. He completed a two-year fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center and received a master's degree in public health at the Columbia Mailman School of Public Health. Dr. Feuerstein's research focuses on improving quality of care and quality of life for patients diagnosed with urologic cancers. Dr. Feuerstein provides care at NewYork-Presbyterian The One, a state-of-the-art center for advanced care with doctors from Columbia in Westchester. The facility offers adult and pediatric care spanning more than 90 specialties and subspecialties, so patients can find the care they and their families need in one convenient location.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Ductal carcinoma in situ (DCIS) represents a clinical crossroads in breast surgery—balancing the risks of over-treatment with the need to prevent invasive cancer. With new data from active monitoring trials, the pressure is on for surgeons to personalize care. Tune in to this essential episode to stay ahead of the curve on DCIS management and to hear expert insights from two leading breast surgical oncologists. Hosts: - Rashmi Kumar, MD, PhD Resident, University of Michigan General Surgery Residency Program Twitter/X: @RashmiJKumar - Melissa Pilewskie, MD Attending Breast Surgical Oncologist, Co-Director of the Weiser Family Center for Breast Cancer, Michigan Medicine Twitter/X: @MPilewskie -  Stephanie Downs-Canner, MD Attending Breast Surgical Oncologist & Physician-Scientist, Memorial Sloan Kettering Cancer Center, Program Director of the Breast Surgical Oncology Fellowship Training Program Twitter/X: @SDownsCanner Learning Objectives: - Define DCIS and explain its significance as a precursor to invasive breast cancer. - Discuss challenges in diagnosing and risk-stratifying DCIS. - Review current standards for surgical and adjuvant management of DCIS. - Understand the implications of new research, including the COMET trial, for low-risk DCIS. - Evaluate patient-centered strategies for managing DCIS and preventing over-treatment. References: - Worni M, Akushevich I, Greenup R, et al. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. J Natl Cancer Inst. 2015;107(12):djv263. PubMed - Francis A, Thomas J, Fallowfield L, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015 Jan;51(16):2296-303. PubMed - Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a non-surgical management strategy for low-grade DCIS: The LORD study. Eur J Cancer. 2015;51(12):1497–1510. PubMed - Toss MS, et al. Ductal carcinoma in situ (DCIS): current management and future directions. Cancer Treat Rev. 2020;90:102091. PubMed - Comparative Effectiveness of Surgery versus Active Monitoring for Low-Risk DCIS (COMET) Trial Results. Early COMET Results: King TA, et al. Surgical excision versus active monitoring for low-risk ductal carcinoma in situ (DCIS): 2-year results of the COMET randomized trial. J Clin Oncol. 2024; e2400110. PubMed Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Dr Irene Grant is an Infectious Disease specialist with expertise in infectious complications in the immunocompromised and unusual infections in the immunocompetent. In the 1980's, in the midst of the HIV/AIDS epidemic, she trained at Memorial Sloan-Kettering Cancer Center in New York City, under Dr. Donald Armstrong (former President of the Infectious Disease Society of America) where she acquired training in Microbiology and Hospital Infection Control. Thereafter she spent years in academic medicine as an Assistant Professor of Medicine at Albert Einstein College of Medicine (1988 – 2000) and later Clinical Assistant Professor of Medicine at New York Medical College, involved in teaching, clinical epidemiology, and research, while treating inner city patients in the HIV “epicenter” in the Bronx. Later, in private practice, she applied her experience investigating unusual illnesses to help her patients sick from hazardous indoor exposures. For the past 24 years, she has evaluated and treated hundreds of debilitated patients and families with environmentally proven hazardous microbial exposures, correlating the development of multi-system illness with hazardous exposures, the reliability of diagnostic tests, and efficacy of anti-fungal treatment.

Send us a textCellular clean up by immune cells and how early-life fructose exposure leads to neurodevelopmental problems.Episode Summary: Dr. Justin Perry talks about the body's constant cellular turnover—about 3 million cells die per second in adults (double in children and women)—handled by phagocytes like macrophages that engulf and digest debris to prevent diseases like lupus. They explore phagocytosis steps, macrophage adaptations in tissues like the brain (microglia), and how high fructose intake impairs microglial function in developing mice, leading to uncleared brain cells and anxiety-like behaviors, with implications for human neurodevelopmental disorders amid rising fructose consumption.About the guest: Justin Perry, PhD is an immunologist and clinical psychologist who leads a lab at Memorial Sloan Kettering Cancer Center focusing on how the body clears dead cells and debris to maintain homeostasis.Discussion Points:The body turns over 1-2% of its 30 trillion cells daily, mostly blood cells, but neurons in kids and endometrium in women turnover at ~2x this ratePhagocytosis involves "find me," "eat me," and digestion signals; failures can cause autoimmunity.Microglia are brain macrophages that uptake fructose via GLUT5 transporter.Early high fructose exposure (comparable to one soda daily) impairs the pruning of synapses and dead neurons.In mice, prenatal or postnatal fructose causes phagocytosis deficits in the prefrontal cortex, leading to heightened fear responses and poor fear extinction, mimicking anxiety disorders.Fructose correlates with rising neurodevelopmental issues like autism and anxiety; it's passed via breast milk, and liquid forms (e.g., sodas) overwhelm metabolic shields more than solid fruits.Macrophages may hold keys to diseases from atherosclerosis to cancer; deleting GLUT5 in microglia reverses fructose's effects, hinting at evolutionary roles in aging or low-oxygen states.Related content:M&M 215: Cancer Metabolism: Sugar, Fructose, Lipids & Fasting | Gary PattiArticle | Dietary Fructose & Metabolic Health: An Evolutionary PerspectiveReference Paper:Study | Early life high fructose impairs microglial phagocytosis and neurodevelopment*Not medical advice.Support the showAffiliates: Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. For all the ways you can support my efforts

In a recent episode of the Oncology-on-the-Go podcast in collaboration with the American Psychosocial Oncology Society (APOS), host Daniel C. McFarland, DO, was joined by Christian J. Nelson, PhD, to discuss the often-overlooked subject of sexual health issues for men after cancer treatment. The discussion emphasized the importance of a nuanced approach to men's health, particularly in the context of genitourinary cancers like prostate and testicular cancer. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY®. He opened the conversation by highlighting that while cancer's physical effects are well-documented, the mental and emotional toll is equally significant and often underappreciated in male patients. He highlighted that the field of psycho-oncology, which began with breast cancer, is now expanding to address men's specific needs. Men, he noted, are less likely to seek mental health support, yet have a higher risk of suicide, particularly at key moments in their cancer journey like diagnosis and recurrence. Nelson, chief of Psychiatry Service, attending psychologist, and codirector of the Psycho-Oncology of Care and Aging Program at Memorial Sloan Kettering Cancer Center, underscored that cancer treatments, especially for prostate cancer, often have profound adverse effects (AEs) that impact a man's sense of self and masculinity.  He detailed the effects of radical pelvic treatments and androgen deprivation therapy (ADT), which can lead to urinary incontinence, erectile dysfunction, and changes in sexual function and body image. These AEs can lead to feelings of being "broken," "inadequate," or "deflated." The pair discussed the "double-edged sword" of normalizing cancer, where patients are told their prognosis is good but are left unprepared for the life-altering AEs. This can lead to a sense of cognitive dissonance and isolation. The conversation stressed the need for clinicians to proactively normalize discussions about sexual health, making it clear that these are standard and expected aspects of the cancer experience. Both clinicians suggested that establishing a trusting relationship with patients is paramount and that referrals to psycho-oncology should be framed as an essential, not optional, component of treatment. They also recommend that clinicians consistently check in with their male patients about emotional and sexual well-being, even long after treatment has ended, to ensure they're coping with the lasting impacts of their experience. 

Rabbi Myrna Matsa, BCC, D. Min., was ordained at the Jewish Theological Seminary and served as a congregational rabbi both as senior rabbi in a small southern congregation and as an assistant in a large mid-western synagogue.  She has earned a Doctor of Ministry degree which brings together psychology and theology, and she is also a Board Certified Chaplain.  She has worked in a variety of medical settings:  hospice, psychiatric hospital, cancer hospital, and nursing homes. As the world remembers Hurricane Katrina on its twentieth anniversary,   Rabbi Matsa comes on NeshamaCast to discuss her experience as Rabbinic Pastoral/Trauma Counselor for Hurricane Katrina Support in the New Orleans, Baton Rouge and the Biloxi/Gulfport Region.  She worked closely with leaders of the various faith communities, both Jewish and non-Jewish, and also lay people within the Gulf area providing them with direct pastoral services during reconstruction, serving as a Jewish referral resource, and interfacing with various mental health associations.  She was sent by the New York Board of Rabbis in partnership with The Jewish Federations of North America. Rabbi Matsa is now retired and resides in Los Angeles. She is a member of NAJC.Articles featuring Myrna Matsa during her community chaplaincy in the Gulf Region:Congregation Beth Israel Moves Into Synagogue, WLOX, May 29, 2009Oil Gushes, Trust Evaporates, Lilith Magazine, Sept. 3, 2010Rabbi Helps Other Clergy to Weather Their Storms, New Jersey Jewish News, Nov. 24, 2010 Rabbi Theodore M. Lichtenfeld is a hospice chaplain with the Visiting Nurse Association of New Jersey. He previously served as rabbi at Congregation Agudat Achim in Schenectady, NY, and at pulpits in New Orleans and New Jersey. Rabbi Lichtenfeld completed a residency in Clinical Pastoral Education at Memorial Sloan Kettering Cancer Center with New York Presbyterian Hospital during the coronavirus pandemic in New York City. He was ordained at the Jewish Theological Seminary in 2001, and also holds ordination from the Academy for Jewish Religion. Rabbi Lichtenfeld, a Philadelphia native, lives in Rockland County, NY, with his wife and three children.Articles about Rabbi Lichtenfeld's Hurricane Katrina experience:Katrina-depleted Jewish Community Begins High Holy Days with Heavy Heart, Religion News Service, Sept. 23, 2006Hurricane Katrina Oral History of Rabbi Ted Lichtenfeld in Jewish Women's Archive, August 21, 2007 Editor's Note: In order to enhance the listening experience, some of the host's questions to Rabbi Matsa were not asked in the live conversation and were added into the recording during the post-production process. ECB  About our host:Rabbi Edward Bernstein, BCC, is the producer and host of NeshamaCast. He serves as Chaplain at Boca Raton Regional Hospital of Baptist Health South Florida. He is a member of the Board of Neshama: Association of Jewish Chaplains. Prior to his chaplain career, he served as a pulpit rabbi in congregations in New Rochelle, NY; Beachwood, OH; and Boynton Beach, FL. He is also the host and producer of My Teacher Podcast: A Celebration of the People Who Shape Our Lives. NeshamaCast contributor Rabbi Katja Vehlow was ordained at the Jewish Theological Seminary and is Director of Jewish Life at Fordham University. She trained as a chaplain at Moses Maimonides Medical Center in New York. Previously, she served as Associate Professor of Religious Studies at University of South Carolina. A native German speaker, she is planning a forthcoming German-language podcast on the weekly Torah portion with a focus on pastoral care. NeshamaCast contributor Chaplain David Balto is a volunteer chaplain at Washington Hospital Center in Washington, D.C. and Western Correctional Insitution, Maryland's maximum security prison. He coordinated the annual National Bikur Cholim Conference. Support NeshamaCast and NAJC with a tax deductible donation to NAJC. Transcripts for this episode and other episodes of NeshamaCast are available at NeshamaCast.simplecast.com and are typically posted one week after an episode first airs. Theme Music is “A Niggun For Ki Anu Amecha,” written and performed by Reb-Cantor Lisa Levine. Please help others find the show by rating and reviewing the show on Apple Podcasts or other podcast providers. We welcome comments and suggestions for future programming at NeshamaCast@gmail.com. And be sure to follow NAJC on Facebook to learn more about Jewish spiritual care happening in our communities.

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. CME information and select publications here.

In this episode of Onc Now, host Jonathan Sackier welcomes Komal Jhaveri, Breast Medical Oncologist and clinical investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Known for her trailblazing work in HER2-positive, HER2-low, and hormone receptor-positive breast cancers, Komal Jhaveri discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field.     Timestamps  00:00 – Introduction  02:50 – What initially drew Komal into oncology   04:45 – The future of breast cancer care  06:13 – Possibility of personalised treatments for patients  07:40 – Antibody-drug conjugates  09:30 – How we define HER2 status  14:40 – HER2-low disease  17:40 – Targeted therapy combinations  20:54 – Endocrine resistance  23:18 – The realities of implementing new therapies   28:40 – Promising initiatives on the horizon  31:30 – Komal's key takeaways  

JCO PO author Dr. Alison M. Schram at Memorial Sloan Kettering Cancer Center shares insights into her JCO PO article, “Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.” Host Dr. Rafeh Naqash and Dr. Schram discuss relevant genomic and clinical features of patients with BRCA-altered uterine sarcoma and the efficacy of PARPis in this population. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and associate professor at the OU Health Stephenson Cancer Center. Today, we are excited to be joined by Dr. Alison Schram, Associate Attending Physician and Section Head of Oral Therapeutics with Early Drug Development and Gynecologic Medical Oncology Services at the Memorial Sloan Kettering Cancer Center, and the senior author of the JCO Precision Oncology article titled, "Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors." At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Schram, thank you for joining us today. I am excited to be discussing this very interesting, unique topic based on what you published in JCO PO. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: What we like to do for these podcasts is try to make them scientifically interesting but at the same time, keep them at a level where our trainees and other community oncology professionals understand the implications of what you've published. So I'd like to start by asking you, what is leiomyosarcoma for those of us who don't necessarily know a lot about leiomyosarcoma, and what are some of the treatment options for these uterine sarcomas? Dr. Alison Schram: Uterine leiomyosarcoma is a rare subtype of uterine cancer, and it represents about 1% of all female cancers in the reproductive tract. This is a rare malignancy that arises from the myometrial lining of the uterus, and it is generally pretty aggressive. In terms of the standard therapy, the standard therapy for uterine leiomyosarcoma includes chemotherapy, generally combination chemotherapy, but despite a few regimens that tend to be effective, the duration of effectiveness is relatively short-lived, and patients with advanced uterine leiomyosarcoma eventually progress and require additional therapy. I will say that localized uterine leiomyosarcoma can be treated with surgery as well. Dr. Rafeh Naqash: Thank you for that description. Now, there are two aspects to what you published. One is the sarcoma aspect, the leiomyosarcoma, and the second is the BRCA mutation. Since we are a precision medicine journal, although we've discussed BRCA a couple of times before, but again, for the sake of our listeners, could you highlight some of the aspects of BRCA and PARP sensitivity for us? Dr. Alison Schram: Yes. So BRCA is a gene that's important for DNA repair, and BRCA mutations can be either inherited as a germline mutation, so one of your parents likely had a BRCA mutation and you inherited one copy. In patients who have an inherited BRCA mutation, the normal cells tend to have one abnormal copy of BRCA, but if a second copy in the cell becomes altered, then that develops into cancer. And so these patients are at increased risk of developing cancers. Specifically, they are at an increased risk of developing ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and a few others. These cancers are considered BRCA-associated tumors. Alternatively, some patients, more rarely, can develop BRCA-altered cancers completely sporadically. So it's a mutation that happens in the tumor itself, and that can lead to impaired DNA repair and promote cancer progression. And those patients are not, they don't have any inherited risk, but just a random event caused a BRCA mutation in the tumor. The reason this is important is because, in addition to it being potentially important for family members, there are certain treatments that are more effective in BRCA-altered cancers. And the main example is PARP inhibitors, which are small molecule inhibitors that inhibit the PARP enzyme, and there is what we call synthetic lethality. So PARP is important for DNA repair, for single-stranded DNA repair, BRCA is important for double-stranded DNA repair, and in a patient that has a cancer that has a BRCA mutation, that cancer becomes more reliant on single-stranded DNA repair. And if you inhibit it with a PARP inhibitor, the cancer cells are unable to repair DNA, and the cells die. So we call that synthetic lethality. PARP inhibitors are FDA approved in several diseases, predominantly the BRCA-associated diseases I mentioned: breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Dr. Rafeh Naqash: That was very beautifully explained. Honestly, I've heard many people explain BRCA before, but you kind of put it in a very simple, easy to understand format. You mentioned this earlier describing germline or hereditary BRCA and somatic BRCA. And from what I gather, you had a predominant population of somatic BRCA, but a couple of germline BRCA as well in your patient population, which we'll go into details as we understand the study. You mentioned the second hit on the germline BRCA that is required for the other copy of the gene to be altered. In your clinical experience, have you seen outside of the study that you published, a difference in the sensitivity of PARP for germline BRCA versus a somatic BRCA that has loss of both alleles? Dr. Alison Schram: So we will get into what's unique about uterine sarcomas in just a minute. In uterine sarcomas, what we have found is that the BRCA mutations tend to be somatic and not germline, as you mentioned. That is in contrast to the other diseases we mentioned, where the vast majority of these tumors are in patients that have germline BRCA alterations. So one thing that's really unique about the uterine sarcoma population and our paper, I believe, is that it is demonstrating an indication for PARP inhibitors in a population that is not characterized by germline BRCA alterations, but truly these by somatic BRCA alterations. If you look at the diseases that PARP inhibitors are validated to be effective in, including the, you know, the ones I mentioned, the BRCA-associated tumors, there's some data in specific context that suggests that perhaps germline alterations are more sensitive to PARP inhibitors, but that's not universal, and it's really tricky to do because the genetic testing that we have doesn't always tell you if you have two hits or just one hit. So you need more complex genetic analysis to truly understand if there is what we call a biallelic loss. And sometimes it's not a second mutation in BRCA. Sometimes it's silencing of the gene by hypermethylation or epigenetics. Some of our clinical trials are now incorporating this data collection to really understand if biallelic loss that we can identify on more complex genetic testing predicts for better outcomes. And we think it's probably true that the patients that have biallelic loss, whether it be germline or somatic biallelic loss, are more likely to benefit from these treatments. That still needs to be tested in a larger cohort of patients prospectively. Dr. Rafeh Naqash: In your clinical experience, I know you predominantly use MSK-IMPACT, but maybe you've perhaps used some other NGS platforms, next-generation sequencing platforms. Have you noticed that these reports for BRCA alterations the report mentioning biallelic loss in certain cases? I personally don't- I do lung cancer, I do early-phase lung cancer as well, but I personally don't actually remember if I've seen a report that actually says biallelic loss. So after this podcast, I'm going to check some of those NGS reports and make sure I look at it. But have you seen it, or what would be a learning point for the listeners there? Dr. Alison Schram: Exactly. And they usually do not. They usually do not explicitly say, “This looks like biallelic loss,” on the reports. The exception would be if there's a deep deletion, then that implies both copies of the gene have been deleted, and so then you can assume that it's a biallelic loss. But oftentimes, when you see a frameshift alteration or a mutation, you don't know whether or not it's a biallelic loss. And you may be able to get some clues based on the variant allele frequencies, but due to things like whole genome duplication or more complex tumor genomics, it's not clear from these reports, and you really do need a more in-depth bioinformatic analysis to understand whether these are biallelic or not. So that is why I suggest that this really needs to be done in the context of a clinical trial, but there is definitely a theoretical rationale for reporting and treating patients with biallelic losses perhaps more so than someone who has a variant of unknown significance that seems to be monoallelic. The other tricky part, as I mentioned, is the fact that there could be epigenetic changes that silence the second copy, so that wouldn't be necessarily evident on a DNA report, and you would need more complex molecular testing to understand that as well. Dr. Rafeh Naqash: Sure. Now, going to your study, could you tell us what prompted the study, what was the patient population that you collected, and how did you go about this research study design? Dr. Alison Schram: It's actually a great story. I was the principal investigator for a clinical trial enrolling patients regardless of their tumor type to a combination of a PARP inhibitor and immunotherapy. And this was a large clinical trial that was being done as a basket study, as I mentioned, for patients that have either germline or somatic alterations with advanced solid tumors that had progressed on standard therapy. And the hypothesis was that the combination of a PARP inhibitor and immunotherapy would be synergistic and that there would be increased efficacy compared to either agent alone and that patients who had BRCA alterations were a sensitive population to test because of their inherent sensitivity to PARP inhibitors and perhaps their increased neoantigen burden from having loss of DNA repair. So this large study, it's been published, really did show that there was efficacy across several tumor types, but it didn't seem to clearly demonstrate synergy between the immunotherapy and the PARP inhibitor as compared to what you might expect from a PARP inhibitor alone, and in addition to a couple of cases, perhaps attributable to the immunotherapy. So maybe additive rather than synergistic efficacy. However, what really struck me looking at the data was that there were three patients with uterine leiomyosarcoma with BRCA deletions who had the best responses of anyone on the study. So incredible, durable responses. One of my patients with a complete response that continues to not have any evidence of cancer eight years after the initiation of this regimen. And for those of us that treat uterine leiomyosarcoma, this is unheard of. These patients generally, as I mentioned, respond, if they do respond to chemotherapy, it's generally short-lived and the cancer progresses. And so a complete response nearly a decade later turns heads in this field. The other interesting thing was that these uterine leiomyosarcoma patients had somatic alterations rather than a germline alteration with a second hit, and the diseases that are best validated for being responsive to PARP inhibitors include the BRCA-associated diseases, the ones that you're at increased risk for if you have a germline BRCA mutation, including breast, pancreas, prostate, and ovarian. And so it was very interesting that this disease type that seemed to be uniquely sensitive to PARP inhibitors with immunotherapy was also different in that patients with uterine leiomyosarcoma don't tend to have a high frequency of BRCA alterations, and in patients that are born with a BRCA alteration, there doesn't seem to be a clearly increased risk of uterine sarcomas. So this population really jumped out as a uniquely sensitive population that differed from the prior indications for PARP inhibitors. Given this patient and these couple of patients that we observed on the combination, in addition to some other case reports and case series that had started to come out in small numbers, we wanted to look back at our large cohort of patients at Memorial Sloan Kettering to see if we could really get a better sense of the numbers. How many patients at Sloan Kettering with uterine sarcomas have BRCA alterations? Are they generally somatic or germline? Are there unique features about these patients in terms of their clinical characteristics? How many of them have received PARP inhibitors, and if so, is this just luck that these three patients did so well, or is this really a good treatment option for patients with BRCA-altered uterine sarcomas? And so we did this retrospective analysis identifying the patients at Sloan Kettering who met these criteria. So in total, we found 35 patients with uterine sarcomas harboring BRCA alterations, and the majority were leiomyosarcoma, about 86% of them had leiomyosarcoma, which is interesting because there are other uterine sarcomas, but it does seem like BRCA alterations tend to be more often in the leiomyosarcomas. And 13 of these patients with uterine leiomyosarcoma were treated with PARP inhibitors in the recurrent or metastatic setting with about half of those patients having an overall response, so that's a significant tumor shrinkage that sustained, and a clinical benefit rate of 62%. And if we look at the patients that had these BRCA2 deep deletions, which was the patient I had that had this amazing response, the overall response rate jumped to 60% and the clinical benefit rate to 80%. And we defined clinical benefit rate as having maintained on the PARP inhibitor without evidence of progression at six months. So this is really impressive for patients with a difficult to treat disease. And we couldn't do a randomized controlled trial comparing it to chemotherapy, but looking retrospectively at outcomes on chemotherapy studies, this was very favorable, particularly because many of these patients were heavily pretreated. So to get a sense of, you know, how this might compare to chemotherapy, we tried to use patients as their own internal controls, and we looked at how long patients were maintained on the PARP inhibitor as compared to how long they were on the treatment just prior. And we used a ratio of 1.3 to say if they were on the PARP inhibitor for 1.3 times what their previous treatment was or longer, that is pretty clearly better, more of a benefit from that regimen. And the majority of patients did meet that bar. So 58% had a PFS ratio greater than 1.3, and the average PFS ratio was 1.9, suggesting, you know, you would expect the the later lines of therapy to actually not work as well, but this suggests that it's actually working better than the immediately prior line of therapy, to me, suggesting that this is truly a good treatment option for these patients. Dr. Rafeh Naqash: Very interesting. And you mentioned that individuals with tumors having deep deletions were probably more responsive. How did you figure out that there was biallelic loss or deep deletions? Was that part of an extended analysis that was done subsequently? Dr. Alison Schram: So the deletions reported on our report, if it's a biallelic deletion, that is the one biallelic molecular alteration that would be reported. So those are, by definition, biallelic, and I think that that may be one of the reasons that's a good biomarker. But also, what's interesting is that if you have both copies deleted of BRCA, you can't develop reversion mutations. So one of the the known mechanisms of resistance to PARP inhibitors in patients who have BRCA alterations are something called a reversion mutation where, if you have a frameshift alteration, for example, in BRCA that makes BRCA protein nonfunctional, you can develop a second mutation that actually puts the DNA back in frame, and a functional protein is now made. And so a mechanism of resistance to PARP inhibitors is actually reverting BRCA to a wild-type protein, and then BRCA's synthetic lethality no longer makes sense and is no longer effective. But if you've deleted both copies of BRCA, you don't have the ability to restore the function, and you can't develop reversion mutations. And that's perhaps why, you know, my patient and others have had these prolonged responses to PARP inhibitors because you don't have the same ability to develop that mechanism of resistance. Dr. Rafeh Naqash: I remember thinking a year and a half back, I had an individual with prostate cancer and with BRCA2, and using liquid biopsy, I had a reversion mutation that we caught. In your practice, have you seen the utility of doing the serial liquid biopsies in these individuals to catch these reversion mutations? Dr. Alison Schram: Yes, absolutely. And in patients that have the ability to develop a reversion mutation, serial cell-free DNA can catch it, but the caveat is that it doesn't always. So if you see an acquired reversion mutation in cell-free DNA, that can be helpful, particularly if you're planning on putting the patient on another line of therapy that might require a dysfunctional BRCA. So if you're putting them on a clinical trial with a PARP combination and the rationale is that they're sensitive because they don't have a functional BRCA, you would want to know if they developed a reversion mutation, and serial cell-free DNA can definitely identify these reversion mutations. Some of the major clinical trials in ovarian cancer have done serial cell-free DNA and have demonstrated the utility of that approach. The caveat is that some of these reversion mutations are not readily caught on cell-free DNA because they're more complex reversion mutations, or they're not, the part of the gene that develops the reversion mutation is not tiled on the panel. And so it doesn't always catch the reversion mutations. Also, depends on the cell-free DNA shedding, depends on the tumor volume and other factors. And we published a related paper of a patient, it was a really interesting case of a patient with prostate cancer who was on a PARP inhibitor and developed what appeared to be a single reversion mutation on one sample, had negative cell-free DNA, single reversion mutation in a tissue biopsy, and then developed disease progression. And we did an autopsy, and the patient kindly consented to an autopsy, and at the time of autopsy, there were 10 unique reversion mutations identified across 11 metastases. So almost each metastasis had a unique reversion mutation, and only one of them had been seen premortem on a tissue biopsy and not on a cell-free DNA. But that autopsy really drove home to me how much we're missing by doing clinical testing in real time and we really don't know the entire genomic complexity of our patients by doing single samples. And theoretically, cell-free DNA can catch DNA from all the metastases, so you might think that that would be a solution, and it definitely can catch reversion mutations that are not seen in a single biopsy, but you really need to do it all. I mean, you need to do the tissue biopsy sampling, you need to do cell-free DNA, and probably one cell-free DNA test is not enough. Dr. Rafeh Naqash: Thank you, again, for that very nice explanation. Now, one quick provocative question. I remember when I was training, the lab that I used to work in, they used to do a lot of phosphorylation markers for DNA damage response, like phospho NBS, RAD51. Have you seen anything of that sort on these biallelic BRCA mutations where tumors are responding, but they also have a very high signature on the phosphorylation side, and it may or may not necessarily correspond to HRD signatures, but have you noticed or done any of that analysis? Dr. Alison Schram: I think that it would be great to do that analysis. And some of the work we're doing now is actually trying to dig a little bit deeper in our cohort of patients to understand are these HRD-positive tumors? Does HRD positivity correlate with response to BRCA alterations? In terms of the functional assays, I would love to be able to do a functional assay in these samples. One of the challenges is that this was a retrospective study and many of the patients were previously treated as standard of care or off-label with these agents, and so we didn't have prospective tissue collection, and so we're really limited by the tissue that was collected as part of standard of care and the consent forms that the patient signed that allow us to do genomic and molecular testing on their samples. So, I think that is hopefully future work that we will do and others will do. Dr. Rafeh Naqash: Sure. Shifting gears to your career trajectory, I'd like to spend a couple of minutes there before we end the podcast. So Dr. Schram, you've obviously been a trailblazer in this space of drug development, early-phase trials. Can you give us a brief synopsis of your journey and how you've successfully done what you're doing and what are some of the things that drive you? Dr. Alison Schram: Well, thank you for saying that. I don't know if that's true, but I'll take the bait. I've been interested in oncology since college and was always very interested in not only the science of oncology but of course, treating patients. And in medical school, I did basic science research in a laboratory and it was very inspiring and made me want to do research in oncology in addition to clinical care. When I became an oncology fellow, I was presented with a very difficult question, which is, “Do you want to be a lab PI and be in the lab, or do you want to do clinical care and clinical research?” And I couldn't choose. I found a mentor who thankfully really had this amazing vision of combining the two and doing very early drug development, taking the data that was being generated by labs and translating it into patients at the earliest stage. So, you know, phase one drug development in molecularly targeted therapies. And so I became very interested as a fellow in early drug development and this ability to translate brand new molecular insights into novel drugs. And I joined the- at Sloan Kettering, there was the Early Drug Development, it was actually a clinic, it was called something different, and it was very fortuitous. My last year of fellowship, the clinic became its own service with the ability to hire staff at Sloan Kettering, and I was the first ever hire to our Early Drug Development Service. And that really inspired me to try and bring these drugs to patients and to really translate the amazing molecular insights that my colleagues here at Sloan Kettering are discovering, and you know, of course, at other institutions and in pharma. And you know, there 's been an amazing revolution in in drug development over the last several years, and I feel very grateful that I've been here for it. You know, I've been able to take the brilliant insights from my colleagues and put these drugs in patients, and I have the amazing privilege of watching patients in many cases that benefit from these treatments. And so I do mostly phase one drug development and molecularly targeted therapies, and truthfully, I am just very fortunate to be around such brilliant people and to have both patients and labs trust me to be able to deliver these new drugs to patients and hopefully develop better drugs that move forward through FDA approval and reach patients across the country. Dr. Rafeh Naqash: Thank you so much. That was very nicely put. And hopefully our trainees and junior faculty find that useful based on their own career trajectories. Thank you, Dr. Schram, for joining us today. Hopefully, we'll see more of your subsequent work in JCO PO. Thank you for giving us all these insights today. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Alison Schram Disclosures Consulting or Advisory Role Company: Mersana, Merus NV, Relay Therapeutics, Schrodinger, PMV Pharma ,Blueprint Medicines, Flagship Pioneering, Redona Therapeutics, Repare Therapeutics, Endeavor BioMedicines Research Funding Company: Recipient: Your Institution  Merus, Kura, Surface Oncology, AstraZeneca, Lilly, Pfizer , Black Diamond Therapeutics, BeiGene, Relay Therapeutics, Revolution Medicines,  Repare Therapeutics, PMV Pharma, Elevation Oncology, Boehringer Ingelheim Travel, Accommodations, Expenses Company: PMV Pharma 

  As a young person starting over in a new country—one where she didn't even yet know the language—young Yelena faced no shortage of challenges. But she also found opportunity she believes might not have existed in her native country.  “As an Armenian individual growing up in Azerbaijan, going by my parents' and my family's experience, I don't think I would have had an opportunity to be a physician there,” Dr. Janjigian says. “There was a clear limitation on who got to be a physician, and it's a prestigious position anywhere in the world. As a relative minority, I wouldn't have been able to do that. My parents certainly had the courage it took to leave and to come to a foreign country.”  That same brand of courage led Dr. Janjigian to her current work as a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center. A specialist in esophageal and stomach cancer, she presented the results of her gastric cancer clinical trial during the plenary session of this year's ASCO Annual Meeting in Chicago. The presentation was the culmination of more than eight years of work involving nearly 1,000 patients and collaborators. Much of that work, she says, started when she received her first grant from Conquer Cancer, a Young Investigator Award. Receiving that funding, she recalls, was a career-defining moment.      In this episode of Your Stories, Dr. Janjigian speaks with host Dr. Mark Lewis about her journey to become an oncologist, along with her vision for a world where a cancer diagnosis isn't nearly as frightening as it is today. 

“At least some of the answer to these issues of compassion fatigue and burnout have to do making our practice environments the very, very best they can be so that nurses and other clinicians can really connect and care for patients in the ways that they want to be able to do that—and the patients need them to be able to do. I think there's a lot that is here already and will be coming, and I feel pretty optimistic about it,” ONS member Anne Gross, PhD, RN, NEA-BC, FAAN, senior vice president for patient care services and chief nursing officer at Dana-Farber Cancer Institute in Boston, MA, told ONS member Christine Ladd, MSN, RN, OCN®, NE-BC, member of the ONS 50th anniversary committee, during a conversation about burnout and compassion fatigue in oncology nursing. Ladd spoke with Gross and ONS member Tracy Gosselin, PhD, RN, NEA-BC, AOCN®, FAAN, senior vice president and chief nursing executive at Memorial Sloan Kettering Cancer Center in New York, NY, about the history of nurse well-being and how nurses and health systems are approaching it today. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: ONS 50th anniversary series Episode 315: Processing Grief as an Oncology Nurse Episode 292: What We Need to Do to Retain Today's Oncology Nursing Workforce Episode 291: Build a Sense of Belonging for Nurses and Patients Episode 264: Stop the Stressors and Improve Your Mental Health as a Nurse Episode 246: Create a Culture of Safety: Fair and Just Culture Episode 160: Build Innovative Staff Education Tools and Resources ONS Voice articles: Critical Event Debriefings Can Reduce Oncology Nurses' Risk of Compassion Fatigue and Burnout ONS Chapters and DNP Candidates Combine Forces to Support Oncology Nurse Well-Being Step Out of Reality With Virtual Breaks to Support Your Wellness at Work Clinical Journal of Oncology Nursing articles: Burnout and Well-Being: Evaluating Perceptions in Bone Marrow Transplantation Nurses Using a Mindfulness Application Engaging Nurse Residents Through Poetry Strategies to Mitigate Moral Distress in Oncology Nursing ONS Nurse Well-Being Learning Library ONS Communities ONS Chapters Connie Henke Yarbro Oncology Nursing History Center Oncology Nursing Foundation Resiliency Resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Gross: “I was on an oncology unit early in practice. And just like today, we were dealing with very sick patients. We were dealing with death and dying. We were administering very toxic treatments and really pushing a field forward in oncology. So there were similar challenges, but I think different from today. There weren't the kind of resources; there wasn't the body of work that's been done today around compassion fatigue and burnout, work-life balance, and things like that. There was not that body of literature and science like there is today. And so there was more of a grassroots kind of support building in the clinical environment that I think I experienced.” TS 2:35 Gosselin: “I think there's also a piece when we think about nurses in the work we do—we also have families. We have aging parents and children. And sometimes that burnout is multifactorial in that we have family obligations and other obligations that make it really hard. And for some people, they say work is their escape from some of that. Yet it's all hard to balance sometimes.” TS 8:09 Gosselin: “It's this question that people like Anne, myself, other chief nurses are saying. If we add this new technology, what are we going to take away? Do we need another alarm to ring to the phone or to their badge? How much can you ask people to do and not be distracted when they're at point of care delivering patient care? Technology should never be a distractor, nor should it tell us how to practice. The technologies we have today—I'm like, ‘Wow, I wish I had that when I started my career.' And yet there's also a double-edged sword to that. I think we have to balance when we think about care and care delivery.” TS 16:36 Gross: “There are so many resources, first of all, that ONS provides to all of us at all levels and in all points in our career and our path from novice to experts. And the needs, though, are the same. Whether you're a novice nurse or whether you're a very experienced nurse, you need to continue to learn and to get new information, and ONS is an incredible resource for that. … As I think both of us keep alluding to and emphasizing here, you also need that connection to other people. And that's what ONS provides—that opportunity to get connected to other people that might be working in some other part of the country or other part of the world but is dealing with similar things that you're dealing with. So it provides that opportunity, and then it also provides an opportunity to get involved. I think when you can get involved and be part of solving a problem, it doesn't then control you and you won't feel defeated by it.” TS 22:24

Breaking Barriers, Making Healthy Choices, and Embracing Survivorship Breaking Barriers, Making Healthy Choices, and Embracing Survivorship. In this episode Yonni and Heather sit down with Dr. Laurie Kirstein from Memorial Sloan Kettering Cancer Center, who made history as the first female chair of the American College of Surgeons' Commission on Cancer. We will talk about breaking glass ceilings, access to quality healthcare, pain management and the impact of smoking on women's health outcomes. Dr. Laurie Kirstein is an Attending Breast Surgeon at memorial string Cancer Center. She attended downstate medical school, Montefiore Medical Center/Albert Einstein University for residency and Massachusetts General Hospital for Breast Surgery fellowship. Prior to arriving at Memorial Sloan Kettering she was attending surgeon and Breast Fellowship Director at the Rutgers Cancer Center Institute of New Jersey. At Memorial SloanKettering she is the Surgical Site Director for their Monmouth, NJ location. She is the current Chair for the American College of Surgeon's Commission on Cancer. She is the lead for the national quality improvement project Breaking Barriers: overcoming barriers to cancer care across America. Her research interests include surgical decision for breast cancer, postoperative pain management and tobacco cessation for cancer patients. Find Yonni & Heather here https://www.herhealthcompass.com/

Welcome to Season 16! We're kicking off a brand-new season with a fantastic lineup of episodes ahead, and I'm so glad you're here.It's been a wonderful summer in New Haven—I spent time with family, snuck away to Vermont, and reconnected with friends. One highlight was attending the Parents Fundraising Conference at NYU, hosted by Cory Williams. I had the honor of presenting during a plenary session alongside Claudia Taylor Overstrom, chair of Yale's Parents Leadership Council.Claudia and her husband Gunnar have led the PLC for the past year. A Yale alumna with a J.D. from Georgetown Law Center, Claudia also serves as President of the Society of Memorial Sloan Kettering Cancer Center.In this first episode of the season—recorded live—we talk about how we work with parents, what partnership really looks like, and why these relationships matter.Let's dive in!

Welcome to the Oncology Brothers podcast! In this episode, we continue our hematology series by diving deep into myelofibrosis (MF) with Dr. Raajit Rampal, an expert in myeloproliferative neoplasms from the Memorial Sloan Kettering Cancer Center. Join Drs. Rahul and Rohit Gosain as they discuss the latest updates in symptom management, emerging treatment combinations, and the importance of timely diagnosis and risk stratification for patients presenting with cytopenias and splenomegaly. Key topics covered in this episode include: • The initial workup and diagnostic criteria for myelofibrosis • The role of next-generation sequencing and bone marrow biopsy • Risk stratification using the IPSS and DIPSS scoring systems • First-line treatment options, including the four available JAK inhibitors: Ruxolitinib, Momelotinib, Fedratinib, and Pacritinib • Supportive care strategies for managing anemia and thrombocytopenia • The importance of clinical trials and early referral for transplant Tune in to gain valuable insights into the evolving treatment landscape for myelofibrosis and learn how community oncologists can effectively manage this complex disease. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes in our hematology series and check out our previous discussions!

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

In this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed: 1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma): https://pubmed.ncbi.nlm.nih.gov/29975623/3. Long-term follow-up results of RCT comparing early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumor burden follicular lymphoma: https://pubmed.ncbi.nlm.nih.gov/40306831/4. RELEVANCE RCT: Lenalidomide plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.22.008435. GALLIUM RCT: Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL. https://pubmed.ncbi.nlm.nih.gov/37404773/https://pubmed.ncbi.nlm.nih.gov/28976863/6. Long-term follow-up of mosunetuzumab in relapsed/refractory FL: https://pubmed.ncbi.nlm.nih.gov/39447094/7. Epcoritamab in relapsed/refractory FL: https://pubmed.ncbi.nlm.nih.gov/38889737/8. Phase 3 inMIND RCT: Tafasitamab plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: https://ashpublications.org/blood/article/144/Supplement%202/LBA-1/5343199. Long term follow-up results from the Phase 3 PRIMA trial of rituximab maintenance in Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.19.01073

This week, Brent welcomes Dr. Diane Reidy-Lagunes, a clinical oncologist at Memorial Sloan Kettering Cancer Center, specializing in gastrointestinal cancers such as neuroendocrine, colorectal, and pancreas cancers. They discuss the cutting-edge landscape of cancer prevention and early detection, full-body scans, blood-based cancer screenings, and lifestyle interventions. Dr. Reidy-Lagunes goes in depth on the complexities of cancer biology, the role of genetic versus lifestyle factors, and the emerging field of microbiome research in understanding cancer risk. This episode is an essential primer for anyone looking to better understand cancer prevention and early detection. Hope you enjoy. You can listen to Memorial Sloan Kettering's official podcast, Cancer Straight Talk, hosted by Dr. Diane Reidy-Lagunes, wherever you get your podcasts.

Dr. Pallawi Torka of Memorial Sloan Kettering Cancer Center joins to share highlights from ASCO and EHA 2025 on the evolving landscape of B-cell lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. She offers in-depth insights on the STARGLO study and its recent ODAC review, the POLARGO trial, a rare T-cell leukemia (T-LGL) study, and new data supporting nivolumab-AVD in frontline Hodgkin lymphoma. Additional discussion includes the inMIND trial for follicular lymphoma, the growing role of ctDNA in managing DLBCL, advances in CAR-T cell therapy for CNS lymphoma, and how she is adapting treatment strategies based on favorable vs. unfavorable disease features. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

In this episode of Elevate Care, host Keri Perez engages in an insightful conversation with Tomya Watt, Chief People Officer at AMN Healthcare, about the evolving role of Chief Human Resource Officers (CHROs). Together, they explore how CHROs have transitioned from transactional roles to becoming strategic, solution-driven partners in the C-suite. The discussion highlights the power of data in driving workforce transformation, the importance of aligning talent strategies with business goals, and how holistic workforce solutions and technology integration can elevate patient care and organizational success.Chapters00:00 The Evolving Role of CHROs06:08 Holistic Workforce Solutions and Technology Integration09:23 Aligning Talent Strategies for Workforce TransformationWant to keep the conversation going?Join Tomya for an upcoming Becker's Healthcare webinar:Turn Workforce Risk Into Enterprise Value: The CHRO Playbook

With his fifth appearance, comedian Alex Edelman is the most frequent guest on Working It Out. Since his last appearance, Alex won an Emmy for his HBO stand-up special Just For Us, which Mike was a producer on. Now Alex is back on the road with a new hour of comedy, including a just-announced visit to Carnegie Hall. Alex discusses Boston sports memories, whether AI will replace comedians, and grieving the death of his creative collaborator Adam Brace. Plus, Alex's rocky stint as a hospital clown, and his new job as a writer and actor on Greg Daniels' highly anticipated follow up to The Office: The Paper.See Alex at Carnegie HallPlease consider donating to Memorial Sloan Kettering Cancer Center

Guests: Kenya DeJarnette, Yoga Therapist and Cancer Survivor Tina Paul, Yoga Therapist and Instructor at Memorial Sloan Kettering and MUIHIn this powerful episode, host Dr. Amy Wheeler sits down with yoga therapist Kenya DeJarnette and her former professor Tina Paul for a deeply moving conversation on healing, resilience, and finding one's path through cancer and beyond. Kenya shares her transformational journey from a breast cancer diagnosis to discovering yoga therapy as a lifeline—a practice that reconnected her to her body, her faith, and her purpose.Through heartfelt storytelling, Kenya reflects on how yoga helped her navigate infertility, grief, trauma, and the physical toll of cancer treatment. With grace and courage, she opens up about how being part of a supportive yoga and cancer care community reawakened her fighting spirit and taught her to embrace life with newfound openness.Tina Paul offers a behind-the-scenes look at the integrative yoga therapy work being done at Memorial Sloan Kettering Cancer Center, describing the role of therapeutic presence, breath, movement, and research in supporting those undergoing cancer treatment.Together, the three explore themes of:Nervous system dysregulation and the role of breath and yoga in recoveryFaith, spirituality, and openness to healing across different modalitiesYoga Nidra as a gateway to deeper rest and reconnectionCommunity as medicine for trauma and illnessThe importance of clinical training in yoga therapyHow yoga can bring people back to their true selfKey Quotes:

Pauline is joined by renowned dermatologic surgeon, Anthony Rossi, for a discussion on the latest findings in skin cancer and recommendations for optimal skin health. Dr. Rossi is a double board-certified dermatologist at Memorial Sloan Kettering Cancer Center in New York. He is a highly sought-after surgeon as well as an expert in non-invasive technologies like lasers and the founder of his own skincare line - Dr. Rossi DERM MD®.During this segment, Pauline and Anthony discuss a range of topics, including:skin cancer - how it is caused, how it can be detected, and how it can be treated or, better yet, prevented.skin care - how to maintain healthy skin at all ages and how to prevent signs of aging.safe sun exposure - what to look for in sunscreen and other ways to protect ourselves from exposure. cosmetic procedures - how to determine whether and when to consider plastic surgery in lieu of lasers or topical ointments.skin myths - the most common misconceptions about beauty products and treatments.future technologies - the most exciting and promising developments in skincare research.Tune in to learn more about staying sun-safe and skin-smart this summer!

Dr Andrea Cercek from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, Dr Pashtoon Kasi from City of Hope Orange County in Irvine, California, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, and Dr J Randolph Hecht from the UCLA David Geffen School of Medicine in Santa Monica, California, discuss recent updates on available and novel treatment strategies for colorectal cancer. CME information and select publications here.

Dr Andrea Cercek from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, Dr Pashtoon Kasi from City of Hope Orange County in Irvine, California, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, and Dr J Randolph Hecht from the UCLA David Geffen School of Medicine in Santa Monica, California, discuss recent updates on available and novel treatment strategies for colorectal cancer. CME information and select publications here.

Dr Andrea Cercek from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, Dr Pashtoon Kasi from City of Hope Orange County in Irvine, California, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, and Dr J Randolph Hecht from the UCLA David Geffen School of Medicine in Santa Monica, California, discuss recent updates on available and novel treatment strategies for colorectal cancer. CME information and select publications here.

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

In our June episode, Dr. Martin Karpeh from Northwell Health helped us kick off Men's Health Awareness Month, examining the unique challenges men face and sharing simple steps they can take to take charge of their health. In this month's Key Note, Dr. Karpeh talks about his participation in a panel discussion that explored the impact that prostate cancer has on Black men. To view the video, visit The Unspoken Truth: A Dialogue on Prostate Cancer Among Black Men.   The Takeaway We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Start your health journey by making an appointment with your primary care physician to know your numbers. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Due for a screening? Check out www.1199SEIUBenefits.org/get-screened Find healthy recipes and meal-prep tips at www.1199SEIUBenefits.org/food-as-medicine. Visit the Healthy Living Resource Center for wellness tips, information and resources; www.1199SEIUBenefits.org/healthyliving. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: www.1199SEIUBenefits.org/videos. Visit our  YouTube channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents.   Martin Karpeh, MD, is the director of surgical oncology at the Northwell Health Cancer Institute for Northwell facilities across eastern Long Island. He is based at Huntington Hospital, where he is chair of surgery. Dr. Karpeh specializes in gastrointestinal tumors, including stomach and esophageal cancer, and cancers of the gastroesophageal junction. In the 1990s, he helped introduce minimally invasive laparoscopic staging techniques that now guide treatment decisions, helping doctors determine whether patients receive chemotherapy before surgery for gastroesophageal junction cancer. He also treats soft tissue sarcomas and skin cancers, including melanoma, squamous cell carcinoma and Merkel cell carcinoma. Dr. Karpeh received his medical degree from the Pennsylvania State University Medical Colleges. He went on to complete his General Surgical Training at the University of Pennsylvania and later a Surgical Oncology Fellowship at Memorial Sloan Kettering Cancer Center, where he spent more than a decade as an attending. He then spent 20 years leading surgical oncology programs at Stony Brook University Medical Center, Mount Sinai Beth Israel Medical Center and Hackensack Meridian Health. For decades, Dr. Karpeh has worked in clinical trial development and frequently refers patients to national and international clinical studies. He is involved in translational research at Cold Spring Harbor Laboratory to identify treatment targets in stomach and esophageal cancers, and has published more than 100 journal articles on stomach and gastroesophageal junction cancer. A member of the International Gastric Cancer Association, the Society of Surgical Oncology and the American Surgical Association, Dr. Karpeh is also the former president of the New York Surgical Society, New York Cancer Society and the Society of Black Academic Surgeons. Additionally, he has been named a Castle Connelly Top Doctor and New York Magazine Top Doctor over many years.

In this episode, we speak with Emily Long Sarro, a board-certified family nurse practitioner specializing in adolescent and young adult (AYA) care at Memorial Sloan Kettering Cancer Center. We focus on the unique challenges AYAs face before, during, and after a stem cell transplant. Emily shares how this age group, defined as 15 years old to 39 years old by the National Cancer Institute, is often overlooked in the healthcare system, stuck between pediatric and adult care settings. They're navigating identity, relationships, careers, and independence—while also managing a serious illness, which can disrupt or halt life milestones.We discuss how Emily approaches AYA care with a holistic mindset—merging clinical treatment with emotional and mental health support. She emphasizes the importance of granting young patients autonomy and private space, especially when families may unintentionally overstep. She urges healthcare providers to always include mental health support in the treatment plan, noting that anxiety, depression, and even PTSD are common in this group, both during and long after treatment.Emily also stresses the need for daily coping tools like journaling, movement, and meditation to supplement infrequent counseling sessions. She encourages us to create trust by really listening, especially since many AYAs feel dismissed in early diagnostic stages due to their age.We then dive into critical but often unspoken topics: fertility preservation, sexual health, and survivorship. Emily outlines time-sensitive fertility options and highlights the emotional toll if these aren't addressed early. She covers the hidden costs of care and offers resource suggestions like Livestrong and Cancer and Careers. She also calls attention to "silent disabilities" that persist post-transplant and affect career and daily function, emphasizing self-advocacy in the workplace. Coworkers and others may not "see" these limitations, but accommodations are often necessary.We discuss milestones missed due to treatment and the emotional weight of watching peers move on through social media. Emily suggests practical ways to stay socially connected, such as virtual events and platforms like Cancer Buddy. For caregivers, she reminds us that support often means just being present and handling small tasks that feel overwhelming to the patient.  It's important to hold space for patients' sadness over missing milestones, but when appropriate, the big picture remains: they may be sacrificing a few milestones now to experience many more later.The episode closes with a deeply moving survivor story—a young man from The Bronx who overcame mistrust in the medical system, underwent a transplant, and now runs a thriving music production business. His resilience and transformation encapsulate the hope and strength that defines this patient group.More:Marrow Masters Season 9, Episode 2, with fertility resources in Show Notes: https://marrowmasters.simplecast.com/episodes/preserving-fertility-through-cancer-treatmentCancerCare – https://www.cancercare.orgImerman's Angels – https://imermanangels.orgLivestrong Fertility – https://livestrong.org/how-we-help/livestrong-fertility/Worth the Wait – https://worththewaitcharity.com/Maggie's Dream (Fertility Preservation Assistance)–https://www.teammaggiesdream.org/Cancer and Careers – https://www.cancerandcareers.orgCancer Buddy App (Bone Marrow Foundation) –https://bonemarrow.org/support-and-financial-aid-2/support/about-cancerbuddyThanks to our Season 17 Sponsors:Leukemia and Lymphoma Society (LLS): https://lls.org/and Incyte: https://incyte.com/ National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd

When your doctor says you need “cancer treatment,” do you know what that actually means?Most people immediately think of chemotherapy. But if you or someone you love is facing a cancer diagnosis, understanding the full range of treatment options could be the difference between feeling overwhelmed and feeling empowered.Dr. Katie Deming sits down with Dr. Jason Konner, a medical oncologist at Memorial Sloan Kettering Cancer Center, to break down the three main types of systemic cancer treatment used today: chemotherapy, targeted therapies, and immunotherapies.Chapters:03:43 – Three Main Types of Cancer Treatment16:34 – Why First-Line Therapies Matter20:48 – Combining Holistic and Conventional Care31:23 – Essential Questions to Ask Your Oncologist43:42 – When and Why to Seek a Second OpinionDr. Konnor shares the insider perspective on second opinions, what those complex drug names really mean, and how to build the kind of relationship with your medical team that leads to better outcomes.You'll learn how some patients unknowingly sabotage their own care and what questions can instantly make you a more informed patient. Listen and learn how to walk into any oncologist's office with confidence, ask the right questions, and truly understand your options.Don't let medical jargon and complex choices keep you in the dark when clear thinking matters most.Reserve Your Spot for the June PSYCH-K® Online Workshop: https://www.katiedeming.com/psych-k-june-2025 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/ Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

In today's episode, supported by Shorla Oncology, we had the pleasure of speaking with Kate Gasparini, PharmD, BCOP, BCPPS, about the use of the oral formulation of imatinib (Imkeldi) for pediatric and adult patients with select leukemias and other malignancies. Gasparini is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Gasparini discussed her role as a clinical pharmacy specialist in pediatric oncology, emphasizing her work in patient care, medication reviews, and supportive care. She also noted challenges in administering treatments to patients with dysphagia and emphasized the need for liquid formulations of common therapies. She explained the significance of the availability of the liquid formulation of imatinib, sharing its benefits for patients who struggle with swallowing. Gasparini also addressed potential barriers to accessing this medication, such as insurance coverage limitations, as well as the importance of considering the volume and palatability of liquid formulations to avoid adverse effects and ensure treatment adherence.

This episode is hosted by Emma Keel, MS, CGC, and features Ying Liu, MD, MPH, a Gynecologic Medical Oncologist & Clinical Geneticist, Memorial Sloan Kettering Cancer Center, and Nicole D. Edison, MD, Clinical Associate of Obstetrics & Gynecology, University of Chicago.The in-depth discussion focuses on managing gynecologic cancer risk in patients with Lynch syndrome, spotlighting the significant updates to the National Comprehensive Cancer Network (NCCN) guidelines released in September 2024 that have shifted the clinical approach for these patients. 

Dr. Comen has dedicated her medical career to saving the lives of women. An award-winning, internationally sought-after clinician and physician-scientist, Dr. Comen works as a medical oncologist with a specialty in breast cancer at Memorial Sloan Kettering Cancer Center and is an assistant professor of medicine at Weill Cornell Medical College. She earned her BA in the history of science from Harvard College and her MD from Harvard Medical School, then completed her residency in Internal Medicine at Mount Sinai Hospital and her fellowship in oncology at Memorial Sloan Kettering Cancer Center. She's the author of All In Her Head: The Truth and Lies Early Medicine Taught Us About Women's Bodies and Why It Matters Today which we discuss on the show today. Join The Newsletter + Receive Your Free List of 52 Selfcare Tips Connect with Michele on Instagram RESOURCES MENTIONED Website: https://www.drelizabethcomen.com/ Instagram: https://www.instagram.com/drelizabethcomen/ Book: All In Her Head: The Truth and Lies Early Medicine Taught Us About Women's Bodies and Why It Matters Today If you enjoyed this interview, please take a moment to rate and review it on Apple podcasts. Your reviews are so appreciated! Not sure how to do it? Instructions are below. XO, Michele Rate + Review: 1. Click on this link 2. Click “View in Apple Podcasts” button 3. Make sure to “Follow” 4. Scroll down until you see “Ratings and Reviews” as shown below.

Julian Adams tried but didn't succeed at retirement after a productive career as a medical chemist with several U.S. Food and Drug Association approvals of cancer-related treatments, including cell therapy for bone marrow transplantation. Soon after, his participation in a Stand Up To Cancer advisory group led to his appointment as the nonprofit's president and CEO. The research organization raises money to advance the diagnosis of numerous cancers. Given rapid technological advancements, our podcast hosts were eager to invite Julian on the show to share how Stand Up To Cancer uses artificial intelligence to aid in this pursuit. Read the episode transcript here. For more information on Stand Up To Cancer and how to donate to the organization, please visit this website. Guest bio Julian Adams, president and CEO of Stand Up To Cancer, is among the world's foremost oncology researchers. He was previously CEO of biopharmaceutical company Gamida Cell and president of R&D at Infinity Pharmaceuticals, where he oversaw development of small molecule drugs to treat cancer. He has also held roles at Millennium Pharmaceuticals, Boehringer Ingelheim, LeukoSite, and ProScript. Adams's recognitions include the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, an anti-cancer drug; the 2012 C. Chester Stock Award Lectureship from Memorial Sloan Kettering Cancer Center; and the 2001 Ribbon of Hope Award for Velcade from the International Myeloma Foundation. He holds more than 40 patents and has authored more than 130 papers and book chapters. He received his bachelor's degree and an honorary doctor of science degree from McGill University and his Ph.D. from MIT in synthetic organic chemistry. Me, Myself, and AI is a collaborative podcast from MIT Sloan Management Review and Boston Consulting Group and is hosted by Sam Ransbotham and Shervin Khodabandeh. Our engineer is David Lishansky, and the executive producer is Allison Ryder. Stay in touch with us by joining our LinkedIn group, AI for Leaders at mitsmr.com/AIforLeaders or by following Me, Myself, and AI on LinkedIn. We encourage you to rate and review our show. Your comments may be used in Me, Myself, and AI materials.

On today's show we're excited to welcome Rick Peng, the Innovation Hub Manager and Digital Licensing Professional at Memorial Sloan Kettering Cancer Center. We talk about how your organization can build an outside-in, external innovation program to deliver outsized results. Rick breaks down the secret sauce of the MSK Innovation Hub, an accelerator program designed to encourage collaborations between Memorial Sloan Kettering Cancer Center and digital health companies, focused on the diagnosis, treatment, and care of cancer patients. We discuss their new Innovation Hub Challenge focused on AI Drug Discovery – and why the access to data sets, is a key unlock for ai driven solutions.

This week, Nick Kroll returns to the podcast to discuss the first season of Adults, the last season of Big Mouth and a movie that Mike cannot seem to remember the name of (I Don't Understand You). Nick and Mike delve into the behind-the-scenes realities of Hollywood writer's rooms, development deals, and who Nick is jealous of. Plus, the thing Nick will always regret saying to Robert DeNiro.Please consider donating to: Memorial Sloan Kettering Cancer Center

June is Men's Health Awareness Month, so this month's episode focuses on the unique health challenges that men face. Men are less likely than women to have regular checkups and have higher rates of chronic conditions. To explore the reasons behind men's reluctance to seek care—and to offer support—we are pleased to be joined by Dr. Martin Karpeh, director of surgical oncology for Northwell Health Eastern Region and chairman of surgery at Huntington Hospital. Dr. Karpeh discusses why it's important for men to make their health a priority, offers insights to why they don't and outlines simple first steps they can take to begin their health journey.   The Takeaway We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Listen to The Unspoken Truth: A Dialogue on Prostate Cancer Among Black Men. Start your health journey by making an appointment with your primary care physician to know your numbers. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Due for a screening? Check out www.1199SEIUBenefits.org/get-screened Find healthy recipes and meal-prep tips at www.1199SEIUBenefits.org/food-as-medicine. Visit the Healthy Living Resource Center for wellness tips, information and resources; www.1199SEIUBenefits.org/healthyliving. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: www.1199SEIUBenefits.org/videos. Visit our  YouTube channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents. Martin Karpeh, MD, is the director of surgical oncology at the Northwell Health Cancer Institute for Northwell facilities across eastern Long Island. He is based at Huntington Hospital, where he is chair of surgery. Dr. Karpeh specializes in gastrointestinal tumors, including stomach and esophageal cancer, and cancers of the gastroesophageal junction. In the 1990s, he helped introduce minimally invasive laparoscopic staging techniques that now guide treatment decisions, helping doctors determine whether patients receive chemotherapy before surgery for gastroesophageal junction cancer. He also treats soft tissue sarcomas and skin cancers, including melanoma, squamous cell carcinoma and Merkel cell carcinoma. Dr. Karpeh received his medical degree from the Pennsylvania State University Medical Colleges. He went on to complete his General Surgical Training at the University of Pennsylvania and later a Surgical Oncology Fellowship at Memorial Sloan Kettering Cancer Center, where he spent more than a decade as an attending. He then spent 20 years leading surgical oncology programs at Stony Brook University Medical Center, Mount Sinai Beth Israel Medical Center and Hackensack Meridian Health. For decades, Dr. Karpeh has worked in clinical trial development and frequently refers patients to national and international clinical studies. He is involved in translational research at Cold Spring Harbor Laboratory to identify treatment targets in stomach and esophageal cancers, and has published more than 100 journal articles on stomach and gastroesophageal junction cancer. A member of the International Gastric Cancer Association, the Society of Surgical Oncology and the American Surgical Association, Dr. Karpeh is also the former president of the New York Surgical Society, New York Cancer Society and the Society of Black Academic Surgeons. Additionally, he has been named a Castle Connelly Top Doctor and New York Magazine Top Doctor over many years.

Parkinson's is a disease that afflicts an estimated 90,000 Americans every year. Current treatment focuses on managing its many symptoms as there is no cure. But a new stem cell-based therapy that creates nerve cells is showing early promise. What's behind this incredible discovery and just how hopeful should patients be? Two of the doctors leading this development, Dr. Lorenz Studer and Dr. Viviane Tabar of Memorial Sloan Kettering Cancer Center, join The Excerpt to share the journey behind this exciting new development.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shining a light on the caregiving journey for lung cancer patients, Dr. Allison Applebaum, founder of the Caregiver's Clinic at Memorial Sloan Kettering Cancer Center, and caregiver Gail Fackler, along with her husband, Jim, speak candidly about the mental health challenges caregivers face, including anxiety, depression, and PTSD. The conversation covers the overwhelming realities of caregiving, from managing medical decisions to coping with guilt and loss of identity. Gail and Jim share raw, honest stories about how caregiving has transformed their lives and relationships. Practical strategies for caregivers—such as task management, setting boundaries, and finding support networks—offer hope and guidance. Learn more about the  critical importance of mental health support for caregivers and the power of community in navigating this journey. Guests Dr. Allison Applebaum, Founding Director, Caregiver's Clinic, Memorial Sloan Kettering Cancer Center Gail and Jim Fackler, Lung Cancer Caregivers and Patient   Show Notes | Transcript | Watch Video

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “Computer-Aided Design and Manufacturing in Free Fibula Reconstruction of the Mandible: Comparison of Long-Term Outcomes with the Conventional Technique” by Bengur, Humar, Saadoun, et al.  Read the article for FREE: https://bit.ly/CADCAMRecon Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

In today's episode, supported by Azurity Pharmaceuticals, we spoke with Michael J. Mauro, MD, about treatment adherence with nilotinib (Tasigna/Danziten) in patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). Dr Mauro is an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Mauro discussed barriers to nilotinib treatment adherence in patients with Ph-positive CML, ways that nonadherence can diminish quality of life and clinical response to treatment, ways that the new formulation of nilotinib addresses adherence issues by reducing the need for fasting, and ongoing research into alternative formulations of other agents that may further improve CML treatment efficacy and tolerability.

In this episode of ASTCT Talks, Dr. Shernan Holtan welcomes Andrew Lin, Manager of Clinical Pharmacy Services of Adult BMT and CTS at Memorial Sloan Kettering Cancer Center, to discuss the evolving role of tacrolimus levels in GVHD prophylaxis within the post-transplant cyclophosphamide (PTCy) era. They explore findings from a recent retrospective study examining whether higher tacrolimus levels offer added protection against GVHD, what this means for toxicity and patient outcomes and how these insights are shaping dosing strategies. The conversation also looks ahead to future research areas, including MMF optimization and the potential for simplified, patient-centered prophylaxis regimens.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “Legislative Impact and Persistent Disparities: Postmastectomy Breast Reconstruction Rates in the United States among 224,506 Patients” by Schafer, Ho, Potoczak, et al. Read the article for FREE: https://bit.ly/LegislativeReconRate Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

Cancer is among the most common and feared diseases in the modern world. Dr. Selwyn Vickers—president and CEO of Memorial Sloan Kettering Cancer Center—joins host Mark Labberton to discuss how precision oncology, data, and faith are transforming cancer treatment. A distinguished cancer surgeon and pancreatic cancer researcher, Vickers explains how groundbreaking advances in genomics, immunotherapy, and AI are transforming once-lethal diagnoses into survivable and even chronic conditions. Together, they explore not only the cutting-edge science of cancer care but also the spiritual, emotional, and social dimensions that affect every patient and caregiver. Resonating with themes of suffering, hope, and resurrection, this conversation offers clarity, compassion, and courage for all who are affected by cancer—from those newly diagnosed, to medical professionals, to grieving families and curious listeners. Episode Highlights “We're getting to a point where we will, in the next five to seven years, have a much better chance to cure people—and to make pancreatic cancer a chronic illness.” “We are in what's somewhat coined the golden age of cancer research.” “Cancer is a disease that creates an existential threat in ways no other illness does.” “If a tumour forms, it means your body's immune system has made a social contract with the cancer.” “We changed the diagnosis in 10–12 percent of the patients who come to us—sometimes from cancer to no cancer.” “Cancer care is a team sport. And our patients often inspire us more than we help them.” Helpful Links & Resources Memorial Sloan Kettering Cancer Center BioNTech – creators of mRNA vaccines for COVID and cancer CAR T-Cell Therapy Overview (Cancer.gov) Tim Keller on cancer and hope Emma Thompson's Wit (HBO) BRCA1 and BRCA2 Genes and Cancer Risk MSK-IMPACT: Next-Gen Tumor Profiling About Selwyn Vickers Selwyn M. Vickers, MD, FACS, is the president and CEO of Memorial Sloan Kettering Cancer Center (MSK) and the incumbent of the Douglas A. Warner III Chair. He assumed the role on September 19, 2022. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars. He has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Additionally, he has served as president of the Society for Surgery of the Alimentary Tract and the Southern Surgical Association. Vickers is the immediate past president of the American Surgical Association. He also continues to see patients. In 1994, he joined the faculty of the University of Alabama at Birmingham (UAB) as an assistant professor in the Department of Surgery, where he was later appointed to professor and the John H. Blue Chair of General Surgery. In 2006, Vickers left UAB to become the Jay Phillips Professor and Chair of the Department of Surgery at the University of Minnesota Medical School. Born in Demopolis, Alabama, Vickers grew up in Tuscaloosa and Huntsville. He earned baccalaureate and medical degrees and completed his surgical training (including a chief residency and surgical oncology fellowship) at the Johns Hopkins University. Vickers completed two postgraduate research fellowships with the National Institutes of Health and international surgical training at John Radcliffe Hospital of Oxford University, England. Vickers and his wife, Janice, who is also from Alabama, have been married since 1988. They have four children. Show Notes The ongoing threat and fear of cancer How Selwyn Vickers got into medicine Pancreatic cancer: Vickers's expertise “We are in what's somewhat coined the golden age of cancer research.” Sequencing the human genome “Is there a drug that might target the mutation that ended up creating your cancer?” Cancer as both a medical and existential diagnosis The revolution of precision oncology through human genome sequencing ”It takes a billion cells to have a one centimetre tumor.” Immunotherapy: checkpoint inhibition, CAR T-cell therapy, and vaccines Cellular therapy:   ”Taking a set of their normal cells and re-engineering them to actually go back and target and attack their tumors. … We've seen patients who had initially a 30 percent chance of survival converted to an 80 percent chance of survival.” “We know in many tumours there's something called minimal residual disease.” “Immunizing yourself against cancer is a significant future opportunity.” Managing the power of data with AI and computational oncology Cancer-care data explosion: the role of computational oncologists Cancer vaccines: breakthrough mRNA treatment for pancreatic cancer ”Didn't ultimately win. We had to suffer through her losing her life, but was so appreciative that she got much more than the six months she was promised.” Tumour misdiagnoses and the importance of specialized expertise Pancreatic cancer challenges: immune cloaking and late-stage detection In the past, one in four would die from the operation for removing pancreatic cancer Long-term survival Future of cancer detection: AI-based medical record analysis and blood biopsies More accurate blood tests to confirm conditions Using AI to select those who are high-risk for cancer Pastor Tim Keller died of pancreatic cancer. In the past, “your doctor … helped you learn how to die.” ”[God's] given man the privilege to discover those things that have been hidden. And over time we've gradually uncovered huge opportunities to impact people's lives.” The state of breast cancer research and treatment “If you get the diagnosis of breast cancer, you have a 90 percent chance to survive and beat it over a five-year period of time.” ”In general, we're in a great state of understanding how to treat breast cancer, how to detect it early, and then have selective and targeted mechanisms to prevent it from coming back.” Prostate cancer research and treatment Theranostics: using a specific antibody to target cancer cells specifically Pediatric cancer:  ”We actually treat more children for cancer than any hospital in America now, but in general, the survival for pediatric cancers is greater than 80 percent.” Emotional, psychological, and spiritual toll of cancer: importance of psycho-oncology How Sloan Kettering developed psycho-oncology to help cancer patients with mental and spiritual health Personal story: how a cafeteria worker empowers patients through food choices “We give back to them the right to choose what they get to have on their tray.” Cancer treatment is a team sport. Wit (film, Broadway play)—actress Emma Thompson plays a cancer patient studying the work of John Donne on death Socioeconomic and racial disparities in cancer care outcomes The healing role of community, support teams, and compassionate listening The importance of listening to cancer patients who are preparing to die The spiritual courage of patients and the transformative power of faith “Our patients often help us. We see the grace with which they often handle that journey.” The inspiration behind becoming a doctor: family legacy and human impact Terminal care: the sacred responsibility of walking with patients to the end Cancer research and treatment as a Christian vocation and expression of humanity Production Credits

In today's episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discussion focused on early clinical findings with zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), both of which are RAS(ON) inhibitors under investigation for the treatment of patients with RAS-mutant NSCLC. Zoldonrasib, a KRAS G12D-selective tri-complex inhibitor, was evaluated in a phase 1 trial (NCT06040541) in patients with previously treated, advanced KRAS G12D–mutated solid tumors, including NSCLC. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was highlighted in another phase 1 trial (NCT05379985) in patients with advanced RAS-mutant tumors, including previously treated NSCLC; notably, this AACR presentation focused on the association between early on-treatment circulating tumor DNA level reduction and clinical response with the agent. In this episode, Dr Arbour shared insights into the mechanisms of action behind these therapies, their respective clinical trial designs, and the potential implications that early data with the agents may have for the evolving RAS-mutant NSCLC treatment paradigm.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “The Financial Impact of a Cosurgeon in Breast Microsurgery” by DeVito, Ke, Park, et al. Read the article for FREE: https://bit.ly/CosurgeonFinance Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/How would your life transform during a 30-day water fast?Dr. Katie Deming is joined by her client Donna DiPane and medical oncologist Dr. Jason Konner from Memorial Sloan Kettering Cancer Center to share an extraordinary healing journey. Donna recently completed a 30-day supervised water-only fast as part of her holistic approach to healing from ovarian cancer. What makes this story especially powerful is the collaborative relationship between conventional and holistic medicine.Chapters:00:17:00 – The fear wasn't just about cancer00:22:00 – I unzipped from my body00:31:00 – A message from God at 3 am00:38:00 – When the shell started to crack00:52:00 – Strip it all down to healThey explore how fasting goes far beyond physical detoxification. Donna shares the profound spiritual awakening she experienced, including receiving powerful messages during the night, connecting with her "light body," and finding a deep release from the fear that had dominated much of her life. Dr. Konner offers his perspective as a conventional oncologist, describing his initial concerns about safety and his surprise at witnessing Donna's transformation throughout the process - not just physically, but emotionally and spiritually.Listen and learn about what happens during a fast, from the physical challenges of the first week to the emotional and spiritual openings that can occur as the body and mind clear.Disclaimer: Never attempt prolonged fasting without proper medical oversight as it can be dangerous. Send us a text with your question (include your phone number)Join Dr. Katie at CANCER: FROM FEAR TO HOPE on May 8, 2025https://heal.regfox.com/heal-from-fear-to-hopeCode: KATIERESILIENCE10 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatie MORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/6 Pillars of Healing Cancer Workshop Series - Click Here to EnrollWork with Dr. Katie: www.katiedeming.comFollow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Take a Deeper Dive into Your Healing Journey: Dr. Katie Deming's Linkedin Here Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER:The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose...

Dr. Fiona Lovely is a longevity, health and wellness expert with specialties in menopause medicine, functional neurology and functional medicine.  She is speaking to the topics of women's health around perimenopause and menopause. In this week's episode, Dr. Lovely sits down with Dr. Shelly Latte-Naor — board-certified internist, integrative medicine physician, and menopause care specialist — for a deeply insightful conversation on supporting menopause for all women and in particular,  in cancer survivors. With a background in mind-body medicine and a former leadership role at Memorial Sloan Kettering Cancer Center, Dr. Latte-Naor brings a wealth of expertise in treating treatment-induced menopause and its often-overlooked effects on women's health post-cancer. Together, they explore how cancer treatments like chemotherapy and hormone blockers can trigger sudden and severe menopausal symptoms, often overlooked in survivorship care. Dr. Latte-Naor breaks down the complexities of hormone therapy in breast cancer patients, including safe uses of local estrogen and emerging research on systemic HRT. The Nitty-Gritty: The hidden toll of cancer treatments: How chemotherapy and hormone blockers can fast-track intense menopause—and why the symptoms are so often dismissed. The truth about hormone therapy in breast cancer survivors: what's safe, what's not, and why the conversation is evolving Non-hormonal solutions for hot flashes, night sweats, and sleep issues—including breakthrough medications and integrative approaches Why sleep disruptions are so common after cancer—and how improving sleep can transform recovery, cognition, and mood The emotional toll of “survivorship shock” and how to rebuild trust in your body after treatment Why self-advocacy is critical—and how to ask for the care you deserve You'll hear about non-hormonal treatment options for:  hot flashes, night sweats, and sleep issues, and how foundational good sleep is to healing and recovery. She also shares powerful insights into the emotional experience of “survivorship shock” and why trauma-informed therapy and self-advocacy are key. If you or someone you know is navigating menopause after cancer (or you're just looking for more ways to support a loved one), this episode is a must-listen. It's a rallying cry for women to demand better care, advocate for themselves, and reframe survivorship as an ongoing journey—one that includes emotional healing, educated choices, and open, honest conversations. You can find more about Dr. Shelly Latte-Naor at shellylattenaormd.com and follow her on Instagram or TikTok. Thank you to our sponsors for this episode:

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue:   “The Financial Impact of a Cosurgeon in Breast Microsurgery” by DeVito, Ke, Park, et al.   “Legislative Impact and Persistent Disparities: Postmastectomy Breast Reconstruction Rates in the United States among 224,506 Patients” by Schafer, Ho, Potoczak, et al.   “Computer-Aided Design and Manufacturing in Free Fibula Reconstruction of the Mandible: Comparison of Long-Term Outcomes with the Conventional Technique” by Bengur, Humar, Saadoun, et al.   Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery.   READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection   The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.